ストックスクリーナーアプリを入手
6.43
7.22%
-0.50
前日終値:
$6.93
開ける：
$6.59
24時間の取引高:
262.85K
Relative Volume:
1.64
時価総額：
$2.15B
収益：
$417.75M
当期純損益:
$32.27M
株価収益率:
65.95
EPS:
0.0975
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-7.61%
1か月 パフォーマンス:
-14.83%
6か月 パフォーマンス:
-40.57%
1年 パフォーマンス:
-63.47%
1日の値動き範囲:
$6.40
$6.59
1週間の範囲:
$6.40
$7.43
52週間の値動き範囲:
$6.40
$30.36
Telix Pharmaceuticals Ltd Adr Stock (TLX) Company Profile
Compare TLX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TLX
Telix Pharmaceuticals Ltd Adr
|
6.43 | 2.32B | 417.75M | 32.27M | 0 | 0.0975 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Telix Pharmaceuticals Ltd Adr Stock (TLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | 開始されました | Citigroup | Buy |
| 2025-08-28 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-07-03 | 開始されました | H.C. Wainwright | Buy |
| 2025-06-05 | 開始されました | Wedbush | Outperform |
| 2024-11-15 | 開始されました | UBS | Buy |
Telix Pharmaceuticals Ltd Adr (TLX) 最新ニュース
Telix Pharmaceuticals (NASDAQ:TLX) Strengthens Clinical Nuclear Medicine - Kalkine Media
Stock of the day: Telix Pharmaceuticals - IG Group
RBC Capital upgrades Telix Pharmaceuticals stock rating to Outperform - Investing.com
Prostate scan trial aims to reduce unnecessary biopsies for men - stocktitan.net
Telix Pharmaceuticals Within The Evolving Precision Oncology Space - Kalkine Media
Levi & Korsinsky Reminds Telix Pharmaceuticals Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 – TLX - GlobeNewswire Inc.
Telix Pharmaceuticals Ltd. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Sahm
Here's What Analysts Think About Telix Pharmaceuticals (TLX) - Finviz
Shareholders that lost money on Telix Pharmaceuticals Ltd.(TLX) should contact The Gross Law Firm about pending Class ActionTLX - Sahm
Telix Pharmaceuticals Ltd. Sued for Securities Law ViolationsContact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Telix Pharmaceuticals (TLX) Faces Securities Class Action After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Barchart.com
Health conference talk to spotlight Telix therapeutic pipeline and products - Stock Titan
TLX Deadline: TLX Investors Have Opportunity to Lead Telix Pharmaceuticals Ltd. Securities Fraud Lawsuit Filed by The Rosen Law Firm - Barchart.com
TLX 6-DAY DEADLINE ALERT: Hagens Berman Urges Telix Investors to Act by Jan. 9 in Class Action Suit Over SEC Subpoena & FDA CRL on Manufacturing Failures - Sahm
FCX IMPORTANT DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Freeport-McMoRan Inc. Investors to Secure Counsel Before Important January 12 Deadline in Securities Class Action First Filed by the Firm - GlobeNewswire Inc.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. LawsuitTLX - Sahm
TLX DEADLINE: Faruqi & Faruqi Reminds Telix Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2026 - Barchart.com
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Telix Pharmaceuticals Ltd. (TLX)January 9, 2026 Deadline to JoinContact Levi & Korsinsky - Sahm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages F5, Inc. Stockholders to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Prostate scans reshaped treatment for 67% of men in China trial - Stock Titan
[6-K] Telix Pharmaceuticals Ltd Current Report (Foreign Issuer) | TLX SEC FilingForm 6-K - Stock Titan
Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - Finviz
Telix Pharma (TLX) Makes Progress With New Study - Finviz
RBC Capital initiates Telix Pharmaceuticals stock with Sector Perform rating - Investing.com
Telix (ASX: TLX) teams with Varian to integrate PSMA-PET imaging into EBRT - Stock Titan
Telix Pharmaceuticals (TLX) files Form 6-K on first ProstACT Global patient - Stock Titan
ATTENTION NASDAQ: TLX INVESTORS: Contact Berger Montague About a Telix Pharmaceuticals Ltd. Class Action Lawsuit - Stock Titan
Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Telix Pharmaceuticals (TLX) Hit with Investor Lawsuit Alleging Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - Finviz
Investors in Telix Pharmaceuticals Ltd. Should Contact Levi & Korsinsky Before January 9, 2026 to Discuss Your RightsTLX - Finviz
Berger Montague PC Investigating Claims on Behalf of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Investors After Class Action Filing - Stock Titan
TLXTelix Pharmaceuticals Ltd ADR Latest Stock News & Market Updates - Stock Titan
Telix Pharmaceuticals Ltd Adr (TLX) 財務データ
収益
当期純利益
現金流量
EPS
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):